Results 161 to 170 of about 28,869 (265)

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV: A Real-World Data from the Spanish BICSTaR Cohort. [PDF]

HIV AIDS (Auckl)
Inciarte A, Miralles C, Silva-Klug A, Revollo B, García Deltoro M, Portilla J, Antela A, Castaño Carracedo MÁ, De Álvaro C, Ramroth J, González-Cordón A, Mallolas J.   +11 more
europepmc   +1 more source

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection-General and Special Populations. [PDF]

Aliment Pharmacol Ther
Mak LY, Hu TH, Yap DYH.
europepmc   +1 more source

A retrospective comparative study of tenofovir alafenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients: Renal and bone safety versus antiviral efficacy. [PDF]

Medicine (Baltimore)
Wang L, Pi G, Lu D, Wang Y, Sun W.
europepmc   +1 more source

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe [PDF]

, 2017
, , Lodwick, R.
core   +1 more source

Correction: Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial. [PDF]

PLoS One
Sequera-Arquelladas S, Vivancos MJ, Vinuesa D, Collado A, Santos IL, Sorni P, Cabello-Clotet N, Montero M, Font CR, Terron A, Galindo MJ, Martinez O, Ryan P, Omar-Mohamed M, Albendín-Iglesias H, Javier R, Romero A, Vallecillos CG, Calleja MÁ, Hidalgo-Tenorio C.   +19 more
europepmc   +1 more source

Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir. [PDF]

Sci Rep
Kim H, Kim JY, Yoo HJ, Kim LY, Yoo JJ, Kim SG, Kim YS.   +6 more
europepmc   +1 more source

Corrigendum to "Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches" [Mater. Today Bio 13 (2022) 100217]. [PDF]

Mater Today Bio
Paredes AJ, Volpe-Zanutto F, Vora LK, Tekko IA, Permana AD, Picco CJ, McCarthy HO, Donnelly RF.   +7 more
europepmc   +1 more source

Inflammatory Biomarkers Decay After First-Line Antiretroviral Therapy Initiation With Dolutegravir/Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide in Persons With HIV: A Substudy of a Randomized Clinical Trial. [PDF]

Health Sci Rep
Fernandez A, Scevola S, Bonin RR, Saumoy M, Imaz A, Podzamczer D, Tiraboschi J.   +6 more
europepmc   +1 more source

Patient Characteristics and Reasons for Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Retrospective Cohort From a Large Urban HIV Clinic. [PDF]

Cureus
Gao H, Manchukonda B, Simoes P, Hamlyn E, Barber TJ, Hunter A, Hart J, Johnson M, Kinloch-de Loes S.   +8 more
europepmc   +1 more source

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial. [PDF]

Hepatol Commun
Tabataba Vakili S, Hirode G, Zahoor A, Saunthar A, Feld JB, Hansen BE, Syeda A, Janssen HLA, Kukreti V, Kuruvilla J, Prica A, Cheung M, Buckstein R, Hicks L, Coffin CS, Street LE, Disperati P, Chan KK, Crump M, Feld JJ.   +19 more
europepmc   +1 more source